New Delhi : Country’s drug controller General of India (DCGI) has written a strongly worded letter to Rogerio Gaspar, Director, Regulation and Prequalification, WHO informing that all control samples of the products have been found to be complying with specifications. Government’s Central Drug Laboratory (CDL) which conducted quality tests on the samples lifted from Maiden pharmaceuticals – the Sonepat-based company which has been in the dock for allegedly causing deaths of children in Gambia has found the products to be complying with specifications, putting the onus on World Health Organisation (WHO) for “prematurely” blaming an Indian company for the deaths without any “independent verification”.
DGCI finds no violation in Maiden Pharma case as claimed by WHO
Doctor Post is a health news portal tailored to provide updates for medical and healthcare professionals, while remaining open to others interested in accessing general health information. The content on Doctor Post is carefully created and/or edited by a dedicated team of doctors, healthcare researchers, and scientific writers.
© 2024 Doctor Post. All Rights Reserved. Created and Maintained by Creative web Solution
Disclaimer: Use of the site is governed by our terms of use, privacy policy, and advertisement policy. For further details, please refer to our Disclaimer.